An unidentified 79-year-old man was granted exclusive early access to Eli Lilly’s most promising experimental drug this spring. The drug, retatrutide, is still unauthorised by the FDA and not available to the public. Only one person got it. The identity of that person has not been confirmed. But the circumstances have led a number of reporters and medical observers to the same conclusion: the patient was almost certainly Donald Trump.
The reporting comes from STAT News, a life sciences publication that covered the story in detail on June 23. According to STAT, a senior clinician at the National Institutes of Health filed an individual patient expanded access request with the FDA in April 2026, seeking approval for a single unnamed patient to receive retatrutide, Eli Lilly’s triple-hormone obesity drug still in clinical trials. The FDA authorised it. Eli Lilly provided the drug. Neither party would confirm the patient’s identity.
The circumstantial evidence is substantial.
The patient was 79 years old in April. Trump turned 80 on June 14. The patient had been treated with tirzepatide, Eli Lilly’s approved obesity drug Zepbound, for about a year and achieved only moderate weight loss. Trump told reporters in January that he had not taken GLP-1 drugs but that he “probably should.” The patient’s physician advised against bariatric surgery due to age and co-morbidities. Trump has long been known to carry excess weight, and his annual medical exam last month put his BMI close to the threshold for clinical obesity.
STAT reported that the case “drew the interest of top health officials,” a detail the publication’s sources interpreted as evidence the patient was politically influential. An NIH senior clinician filing a compassionate use request that gets noticed at the highest levels of HHS is not the normal course of events for an anonymous citizen.
The White House denied it. Spokesperson Kush Desai wrote that “this application was not for the President.” But the statement was narrow and conspicuously lacked the kind of detail that would settle the question. When STAT asked whether Trump had the conditions cited in the application — obstructive sleep apnea and pulmonary hypertension — Desai pointed to a presidential medical evaluation. That document does not mention either condition.
There is precedent. In 2020, Trump became one of the first people in the country to receive Regeneron’s monoclonal antibody treatment for COVID-19 under compassionate use, before the drug received emergency authorisation. He promoted it heavily afterward. The pattern is consistent: when an experimental drug shows promise, Trump finds a way to get it early.
The drug itself is significant. Retatrutide is the next generation of GLP-1 agonists, more powerful than Ozempic or Zepbound. Eli Lilly’s trial results showed patients lost an average of 28 to 30 percent of their body weight over 80 weeks, approaching the effectiveness of bariatric surgery. The drug has not been approved by the FDA. It is already being sold through unregulated online vendors, but those who obtain it through gray-market sources face risks without medical supervision.
The compassionate use programme — formally called expanded access — was designed for patients with serious or life-threatening conditions who have no other treatment options. It was built for terminal cancer patients and AIDS patients in crisis. Applying it to weight management, even in a complex case with co-morbidities, stretches the original purpose of the programme. One patient receiving an unapproved drug ahead of millions of obese Americans who would benefit from it raises a question the system has not answered well: who gets to jump the line?
Eli Lilly’s CEO David Ricks has a comfortable relationship with the Trump administration. He attended a dinner at Mar-a-Lago earlier this year. The company has reasons to maintain good relations with a president who has shown he can influence drug pricing policy and regulatory decisions. A compassionate use grant for a well-connected patient is not proof of favouritism, but it fits the pattern of how access to experimental medicine actually works in the United States.
The White House denial, the company’s refusal to comment, and the FDA’s silence leave the question unresolved. No one has produced evidence that the patient was Trump. No one has produced evidence that it was not. What is known is that one person got a drug that millions cannot have, and every available clue points in the same direction.